Study assessing the impact of depression and anxiety on prostate cancer patients' quality of life

Not Applicable

• Conditions: Prostate cancer; Cancer; Malignant neoplasm of prostate

• Registration Number: ISRCTN79584810
• Lead Sponsor: ottingham University Hospitals NHS Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-07-27
• Last Update Posted: 10 August 2021
• Study Completion: 2021-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: Male
• Target Recruitment: 150

Inclusion Criteria

1. Patients with prostate cancer starting LHRH agonist therapy, irrespective of stage
2. Ability to give informed consent
3. Performance status 0-2
4. Life expectancy should be more than 6 months

Exclusion Criteria

1. Past or present history of psychiatric problem
2. If a patient scores greater than 11 on the baseline Hospital and Anxiety Scale they will be offered anti-depressant drug treatment and/or a psychiatric referral. In addition they will be asked if they wished to continue in the study. If the patients do not wish to continue at this stage the researchers would not collect any further quality of life information from them
3. Concurrent steroid therapy or treatment with any other antipsychotic/antidepressant/sedative drugs
4. Brain metastases
5. Concurrent radiotherapy
6. Major surgery in last 6 months, e.g. prostatectomy, colectomy etc
7. Major medical illness in last 6 months e.g. pulmonary embolism, myocardial infarction, cerebrovascular accident etc

Study & Design

• Study Type: Observational
• Study Design: Not specified